menu
    • menu
    [{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"OSR Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2024","type":"Collaboration","leadProduct":"BAL0891","moa":"||Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ SillaJen, Inc"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SillaJen, Inc \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Agreement","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0.01,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ SillaJen, Inc"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Basilea Pharmaceutica","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2022","type":"Licensing Agreement","leadProduct":"BAL0891","moa":"Checkpoint protein","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0.33000000000000002,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.33000000000000002,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ SillaJen, Inc","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ SillaJen, Inc"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2012","type":"Inapplicable","leadProduct":"JX-594","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SillaJen, Inc \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2010","type":"Inapplicable","leadProduct":"JX-594","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SillaJen, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SillaJen, Inc \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"JX-594","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SillaJen, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SillaJen, Inc \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Transgene","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Cell & Gene Therapy","year":"2011","type":"Inapplicable","leadProduct":"JX-594","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SillaJen, Inc \/ Transgene","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Transgene"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2017","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Samsung Medical Center","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2011","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Samsung Medical Center","highestDevelopmentStatusID":"8","companyTruncated":"SillaJen, Inc \/ Samsung Medical Center"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2024","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"||Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"SillaJen, Inc \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"SillaJen, Inc \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2011","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase II","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SillaJen, Inc \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"SillaJen, Inc \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Solving Kids' Cancer","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2010","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase I","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"SillaJen, Inc \/ Solving Kids' Cancer","highestDevelopmentStatusID":"6","companyTruncated":"SillaJen, Inc \/ Solving Kids' Cancer"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Microorganism","year":"2015","type":"Inapplicable","leadProduct":"Pexastimogene devacirepvec","moa":"Granulocyte-macrophage colony-stimulating factor","graph1":"Oncology","graph2":"Phase III","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SillaJen, Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"SillaJen, Inc \/ Undisclosed"},{"orgOrder":0,"company":"SillaJen, Inc","sponsor":"ReiThera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ITALY","productType":"Vaccine","year":"2025","type":"Partnership","leadProduct":"SJ-600","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"SillaJen, Inc","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SillaJen, Inc \/ SillaJen, Inc","highestDevelopmentStatusID":"4","companyTruncated":"SillaJen, Inc \/ SillaJen, Inc"}]

    Find Clinical Drug Pipeline Developments & Deals by SillaJen, Inc

    Menu

    SillaJen, Inc

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SJ-600

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : ReiThera

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            ReiThera Partners with SillaJen to Develop & Produce the SJ-600 Series for Clinical Trials

                            Details : Through the partnership, ReiThera will leverage its expertise to conduct advanced development & production of the SJ-600 series, transforming it into a clinical-ready drug capable of entering trials.

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 24, 2025

                            Lead Product(s) : SJ-600

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : ReiThera

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BAL0891,Carboplatin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : OSR Holdings

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            OSR Holdings and SillaJen Sign MOU to Develop Innovative Therapeutics in US Market

                            Details : The collaboration will explore various ways to create synergies between current platform technologies and new drug candidates, including BAL0891, a mitotic checkpoint inhibitor targeting solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            April 22, 2024

                            Lead Product(s) : BAL0891,Carboplatin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : OSR Holdings

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pexastimogene devacirepvec,Cemiplimab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SillaJen Submits CSR to the US FDA for REN026 Study in Patients with RCC

                            Details : Pexa-Vec (pexastimogene devacirepvec) is a vaccinia virus based oncolytic immunotherapy is being evaluated in combination with cemiplimab for metastatic or unresectable renal cell carcinoma.

                            Product Name : Pexa-Vec

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            March 27, 2024

                            Lead Product(s) : Pexastimogene devacirepvec,Cemiplimab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BAL0891

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

                            Details : BAL0891 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 15, 2023

                            Lead Product(s) : BAL0891

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BAL0891

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $14.0 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Basilea Announces Transition Milestone for Oncology Asset BAL0891, Triggering Milestone Payment of USD 4 Milli...

                            Details : BAL0891 is a potential first-in-class mitotic checkpoint inhibitor that drives aberrant tumor cell division leading to tumor cell death. A first poster showed in-vitro data on the activity of BAL0891 against its targets, threonine tyrosine kinase and pol...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $10.0 million

                            December 19, 2022

                            Lead Product(s) : BAL0891

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $14.0 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : BAL0891

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $334.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Basilea Announces Acquisition of Rights for Oncology Asset BAL0891 by SillaJen And Updates Financial Guidance

                            Details : The agreement for a novel kinase inhibitor, BAL0891, a potential first-in-class mitotic checkpoint inhibitor, demonstrates the commitment to enhance lives of patients suffering from advanced solid tumors.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Undisclosed

                            September 19, 2022

                            Lead Product(s) : BAL0891

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Basilea Pharmaceutica

                            Deal Size : $334.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pexastimogene devacirepvec

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma

                            Details : Pexa Vec (Pexastimogene Devacirepvec) is a Microorganism drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Renal Cell.

                            Product Name : Pexa Vec

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            September 26, 2017

                            Lead Product(s) : Pexastimogene devacirepvec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Regeneron Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pexastimogene devacirepvec

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone

                            Details : Pexa Vec (Pexastimogene Devacirepvec) is a Microorganism drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Pexa Vec

                            Product Type : Microorganism

                            Upfront Cash : Inapplicable

                            September 29, 2015

                            Lead Product(s) : Pexastimogene devacirepvec

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JX-594

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 2a Study of Modified Vaccinia Virus to Treat Sorafenib-naïve Advanced Liver Cancer

                            Details : JX-594 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Carcinoma, Hepatocellular.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 10, 2012

                            Lead Product(s) : JX-594

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed

                            SillaJen, Inc

                            South Korea arrow
                            ISPE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JX-594

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Transgene

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carci...

                            Details : JX-594 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            July 15, 2011

                            Lead Product(s) : JX-594

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Transgene

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth